The short version of actin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-04. Anything still debated is marked as such rather than presented as settled.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Because the ELISA can be performed to evaluate either the presence of antigen or the presence of antibody in a sample, it is a useful tool for determining serum antibody concentrations (such as with the HIV test or West Nile virus). It has also found applications in the food industry in detecting potential food allergens, such as milk, peanuts, walnuts, almonds, and eggs and as serological blood test for celiac disease. ELISA can also be used in toxicology as a rapid presumptive screen for certain classes of drugs.
They granted a worldwide sublicense of the technology to a small (less than $100M in sales), innovative company well known for its cutting-edge column technology: Phenomenex. This was a superior strategic move for two reasons. As mentioned above, Merck is not well known for its column manufacturing. Furthermore, having more than one silica monolith manufacturer serves to better validate the technology. Having sublicensed the technology from Merck, Phenomenex introduced its Onyx product line in January 2005. On the other side of monolith technologies are the polymerics. Unlike the inorganic silica columns, the polymer monoliths are made of an organic polymer base. Dionex, traditionally known for its ion chromatography capabilities, has led this side of the field. In the 1990s, Dionex first acquired a license for the polymeric monolith technology developed by leading monolithic chromatography researcher Frantisec Svec while he was at Cornell University. In 2000, they acquired LC Packings, whose competencies were in LC column packings. LC Packings/Dionex revealed their first monolithic capillary column at the Montreux LC-MS Conference. Earlier that year, another company, Isco, introduced a polystyrene divinylbenzene (PS-DVB) monolith column under the brand SWIFT. In January 2005, Dionex was sold the rights to Teledyne Isco's SWIFT media products, intellectual property, technology, and related assets.
Produced by Mike Tomlinson, made by Orlando Television Productions with WGBH 21 October The Mind Benders, in May 1991, the Broadcasting Complaints Commission, ruled that this episode should have been broadcast under the title Open Mind; about the Hemi-Sync method; the Float Centre, in St John's Wood with Samantha O'Connor, which cost £22 an hour; Peter Fenwick and flotation tanks; the EEG Mind Mirror of Geoffrey Blundell; the voice of Robert Monroe, and a hemi-sync session in Cambridge, where 200hz is played in one ear, and 206hz in the other ear; a so-called mind gymnasium in Japan, launched in 1975; Australian psychologist Dorothy Rowe, who questioned the veracity of the methods, which could be explained through the placebo effect, which is often not an unimportant effect on health. Narrated by Peter Jones, produced by Patrick Uden, directed by Gary Burczak, made by Uden Associates. Much of the techniques demonstrated were not dissimilar to techniques advocated by the 1990s Natural Law Party 28 October The Winning Streak, about East German methods in women athletics; with Katrin Krabbe. Narrated by Tony Ward, produced by Mike Johnstone, directed by Nikolas L.
G protein dependent activation of phospholipase C (PLC) which results in the breakdown of the membrane constituent phospholipid, phosphatidylinositol (4,5)-bisphosphate (PIP2) into inositol (1,4,5)-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 is one of the most effective inducers of Ca2+ increase from cytoplasmic pools and from outside the cell via opening Ca2+ channels. DAG in turn is an inducer of protein kinase C (PKC). Activation of the regulatory small GTPase, RAS. The active RAS can in turn activate RAF, a Ser/Thr kinase. In the next step mitogen-activated protein kinases (MAP kinases) are activated. (Also known as extracellular signal-regulated kinases - ERKs or MAP/ERK kinase (MEK)). As a result of the last step, ERK1 and ERK2 are activated. The phosphorylated forms of ERKs can continue the cascade by triggering activation more interacting kinases which results in altered transcriptional activity in the nucleus. Ligand binding to FPR can also induce the activation of CD38, an ectoenzyme of the surface membrane. As a result of activation NAD+ molecules will enter the cytoplasm. NAD+ is converted into cyclic ADP ribose (cADPR), a second messenger which interacts with ryanodine receptors (RyR) on the surface of the rough endoplasmic reticulum. The overall result of the process is increased cytoplasmic Ca2+ levels via the direct pathway described above and also via indirect pathways such as opening of Ca2+ channels in the cell membrane. The sustained increase of Ca2+ is required for directed migration of the cells.
== History == In March 1963 the Danish pharmaceutical company Lundbeck began research into further agents for schizophrenia, having already developed the thioxanthene derivatives clopenthixol and chlorprothixene. By 1965 the promising agent flupenthixol had been developed and trialled in two hospitals in Vienna by Austrian psychiatrist Heinrich Gross. The long- acting decanoate preparation was synthesised in 1967 and introduced into hospital practice in Sweden in 1968, with a reduction in relapses among patients who were put on the depot.
Sources: en.wikipedia.org
Bicodeine is a dimer of codeine which is essentially the codeine analogue of pseudomorphine and is also known as pseudocodeine. It is an occasional component of opium and is also a decomposition product of codeine under certain circumstances.
As chronic obstructive pulmonary disease (COPD) advances, about 35% of patients experience severe weight loss called pulmonary cachexia, including diminished muscle mass. Around 25% experience moderate to severe weight loss, and most others have some weight loss. Greater weight loss is associated with poorer prognosis. Theories about contributing factors include appetite loss related to reduced activity, additional energy required for breathing, and the difficulty of eating with dyspnea (labored breathing). Cancer, a very common and sometimes fatal cause of unexplained (idiopathic) weight loss. About one-third of unintentional weight loss cases are secondary to malignancy. Cancers to suspect in patients with unexplained weight loss include gastrointestinal, prostate, hepatobiliary (hepatocellular carcinoma, pancreatic cancer), ovarian, hematologic or lung malignancies. People with HIV often experience weight loss, and it is associated with poorer outcomes. Wasting syndrome is an AIDS-defining condition. Gastrointestinal disorders are another common cause of unexplained weight loss – in fact they are the most common non-cancerous cause of idiopathic weight loss. Possible gastrointestinal etiologies of unexplained weight loss include: celiac disease, peptic ulcer disease, inflammatory bowel disease (crohn's disease and ulcerative colitis), pancreatitis, gastritis, diarrhea, chronic mesenteric ischemia and many other GI conditions. Infection. Some infectious diseases can cause weight loss.
=== Incorporation === There are two accounts of the incorporation date of W. R. Grace & Co. According to The New York Times, the company was incorporated as part of the estate and successor planning in 1895. The three brothers consolidated most of their holdings into a new private company, incorporated in West Virginia, called W. R. Grace & Company. The consolidation involved W. R. Grace & Co. of New York, Grace Brothers & Co. of Lima, Peru, Grace & Co. of Valparaíso, Chile, William R. Grace & Co. of London, and J. W. Grace & Co of San Francisco. According to its website, W. R. Grace & Co. was incorporated in Connecticut in 1899. The listed capital of $6 million did not include Grace Brothers & Co. Limited in London or its branches in San Francisco, Lima, and Callao, Peru, nor Valparaíso, Santiago, and Concepción, Chile. J. Louis Schaefer, who joined the company as a boy, played a key role in not only W. R. Grace & Company, in which he became a vice president, but also as president of Grace National Bank. Schaefer was a co-executor of the estate of Michael Grace with William's son and corporate successor, Joseph Peter Grace Sr.. J. Louis Schaefer died in 1927.
Later in the eighteenth century the crown sought to decrease the privileges (fueros) of the clergy, restricting clerical authority to spiritual matters and undermining the power of parish priests, who often acted as agents of the crown in rural parishes. By desacralizing power and frontal attacks on the clergy, the crown, according to William B. Taylor, undermined its own legitimacy, since parish priests had been traditionally the "natural local representatives of their Catholic king." In the economic sphere, the crown sought to gain control over church revenues. The Church functioned as one of the largest economic institutions within colonial Spanish America. It owned and retained jurisdiction over large amounts of land, which the crown wanted for itself because of the economic value which could be derived from the land. Moreover, by taking that land for itself, the Crown had the opportunity to cut down the physical presence of the Church to further weaken its ideological and social role within local colonial communities. In a financial crisis of 1804, the crown attempted to call in debts owed the church, mainly in the form of mortgages for haciendas owned by the elites. The Act of Consolidation simultaneously threatened the wealth of the church, whose capital was mainly lent for mortgages, as well as threatening the financial well-being of elites, who depended on mortgages for acquiring and keeping their estates. Shortening the repayment period meant many elites were faced with bankruptcy.
Some of the earliest ancient human civilisations in South Asia originated from areas encompassing present-day Pakistan. The earliest known stone tools in the region, dating to the Lower Palaeolithic (~2 million years ago), were discovered in the Soan Valley of northern Pakistan. The Indus plain region, which covers most of the present-day Pakistan, was the site of several successive ancient cultures including the Neolithic (7000–4300 BCE) site of Mehrgarh, and the 5,000-year history of urban life in South Asia to the various sites of the Indus Valley Civilisation, including Mohenjo-daro and Harappa. Following the decline of the Indus Valley Civilisation, semi-nomadic Indo-European Aryans migrated into the Indian subcontinent around 2000 BCE, perhaps by way of the Khyber Pass. They fused with the indigenous Harappan culture of the Indus Valley, and elements of the pre-Aryan spiritual traditions were assimilated into the developing Vedic tradition. This cultural milieu shaped the Gandhara Civilisation, which flourished at the crossroads of India, Central Asia, and the Middle East, connecting trade routes and absorbing cultural influences from diverse civilisations. By the early Vedic period, parts of the Indus region in present-day Pakistan were populated by numerous tribes that were beginning to coalesce into chieftain-led clans and early kingdoms. During this period, the Vedas, the oldest scriptures of Hinduism, were composed.
Sources: en.wikipedia.org
==== Trinidad and Tobago ==== The destroyer Gravely arrived on 26 October 2025 to spend four days in Trinidad and Tobago, where their country's forces would jointly train with US Marines. Trinidad and Tobago announced additional joint training drills with US Marines in November. Caine would travel to Trinidad and Tobago after the November 2025 Puerto Rico visit to meet with Trinidad and Tobago Prime Minister Kamla Persad-Bissessar; the Caribbean National Weekly stated that the visit came "as the two nations deepen their security collaboration to strengthen regional stability and combat illicit trafficking and transnational criminal organizations". In late November, the US installed a radar system in the island nation, which is useful for aerial surveillance. In December, Trinidad and Tobago approved military aircraft from the US to use the country's airports for operations that are "logistical in nature, facilitating supply replenishment and routing personnel rotations", according to its foreign ministry.
=== Further processing === The N-terminal fMet is removed from majority of proteins, both host and recombinant, by a sequence of two enzymatic reactions. First, peptide deformylase (PDF) deformylates it, converting the residue back to a normal methionine. Then methionine aminopeptidase (MetAP) removes the residue from the chain. MetAP only acts on proteins with second-position residues that are less bulky than valine. The N-terminal fMet, if not removed by PDF, seems to act as a degron, a signal for protein degradation.
Abdominal fullness related to an enlarged spleen (splenomegaly). Enlargement of both the liver and spleen Splenomegaly due to extramedullary hematopoiesis (hematopoiesis occurring outside of the bone marrow) Bone pain Bruising and easy bleeding due to inadequate numbers of platelets Increased risk of thrombosis Cachexia (loss of appetite, weight loss, and fatigue) Fatigue Fevers Chills Weight loss Gout and high uric acid levels Increased susceptibility to infection, such as pneumonia Pallor and shortness of breath due to anemia Leukoerythroblastic smear (tear-drop RBCs, nucleated RBCs, and immature granulocytes) In rarer cases, a raised red blood cell volume Cutaneous myelofibrosis is a rare skin condition characterized by dermal and subcutaneous nodules.
=== United States === Tincture of Opium is available by prescription in the United States. It is regulated as a Schedule II drug (No. 9639) under the Controlled Substances Act. In the United States, opium tincture is marketed and distributed by several pharmaceutical firms, each producing a single formulation of the drug, which is deodorized. Each mL contains 10 mg of anhydrous morphine (the equivalent of 100 mg of powdered opium), other opium alkaloids (except noscapine), and ethanol, 19%. It is available packaged in bottles of four US fluid ounces (118 mL) and 16 US fluid ounces (1 US pt; 473 mL). Tincture of Opium is known as one of many "unapproved drugs" regulated by the U.S. Food and Drug Administration (FDA); the marketing and distribution of opium tincture prevails only because opium tincture was sold prior to the Federal Food, Drug & Cosmetic Act of 1938. Its "grandfathered" status protects opium tincture from being required to undergo strict FDA drug reviews and subsequent approval processes. However, the FDA closely monitors the labeling of opium tincture. Bottles of opium tincture are required by the FDA to bear a bright red "POISON" label given the potency of the drug and the potential for overdose (see discussion about confusion with Paregoric below). Additionally, in a warning letter to a manufacturer of opium tincture in late 2009, the FDA noted that "we found that your firm is manufacturing and distributing the prescription drug Opium Tincture USP (Deodorized – 10 mg/mL).
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.